Paglitaz - Pioglitazone
What is Paglitaz - Pioglitazone?
Paglitaz is a medicine that contains the active substance pioglitazone. It is available in tablets (15, 30 and 45 mg).
Paglitaz is a 'generic medicine'. This means that Paglitaz is similar to a 'reference medicine' already authorized in the European Union (EU) called Actos.
What is Paglitaz - Pioglitazone used for?
Paglitaz is indicated for the treatment of type 2 diabetes in adults (aged 18 years and over), particularly in those who are overweight. It is used in conjunction with diet and exercise.
Paglitaz is used on its own in patients for whom metformin (another antidiabetic medicine) is not suitable.
Paglitaz can also be used in combination with metformin in patients who are not satisfactorily controlled on metformin alone, or with a sulphonylurea (another type of antidiabetic medicine) when metformin is not adequate ('dual therapy').
Paglitaz can also be used in combination with metformin and a sulphonylurea in patients who are not satisfactorily controlled despite dual therapy ("triple therapy") by mouth.
How is Paglitaz - Pioglitazone used?
The recommended starting dose of Pioglitazone Krka is 15 or 30 mg once a day. This dose can be increased after one or two weeks to 45 mg once a day if better blood glucose (sugar) control is needed. Pioglitazone Krka should not be used in patients on dialysis (a blood clearance technique used in people with kidney disease). The tablets should be swallowed with water.
Treatment with Pioglitazone Krka should be re-examined after 3-6 months and its administration discontinued in the case of patients who are not benefiting sufficiently. Prescribers should confirm continuity of treatment benefits for patients in further review.
How does Paglitaz - Pioglitazone work?
Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or where the body is unable to use insulin effectively. The active substance in Pioglitazone Krka, pioglitazone, makes cells (fat, muscle and liver) more sensitive to insulin, which allows the body to make better use of the insulin it produces. As a result, they are reduced. blood glucose levels and this helps control type 2 diabetes.
How has Paglitaz - Pioglitazone been studied?
Since Pioglitazone Krka is a generic medicine, studies in patients have been limited to tests to determine its bioequivalence to the reference medicine, Actos. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.
What are the benefits and risks of Paglitaz - Pioglitazone?
Because Pioglitazone Krka is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Why has Paglitaz - Pioglitazone been approved?
The CHMP concluded that, in accordance with EU requirements, Pioglitazone Krka has been shown to have comparable quality and to be bioequivalent to Actos. Therefore, the CHMP considered that, as in the case of Actos, the benefits outweigh the identified risks and recommended the granting of the marketing authorization for Pioglitazone Krka.
More information about Paglitaz - Pioglitazone
On 21 March 2012, the European Commission issued a "marketing authorization" for Pioglitazone Krka, valid throughout the European Union.
For more information about Pioglitazone Krka therapy, read the package leaflet (included with the EPAR) or contact your doctor or pharmacist.
Last update of this summary: 08-2011.
The information on Paglitaz - Pioglitazone published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.